Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).
- R Dummer (Author)
- D Gusenleitner (Author)
- CD Campbell (Author)
- C Lebbe (Author)
- V Atkinson (Author)
- M Mandala (Author)
- PD Nathan (Author)
- A Arance (Author)
- Erika Richtig (Author)
- N Yamazaki (Author)
- C Robert (Author)
- D Schadendorf (Author)
- HAH Tawbi (Author)
- PA Ascierto (Author)
- A Ribas (Author)
- K Flaherty (Author)
- E Gasal (Author)
- JC Brase (Author)
- GV Long (Author)
Activity: Talk, presentation or poster › Poster